Combination of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with intraperitoneal chemotherapy as a treatment modality for persistent ovarian cancer

Persistent minimal residual disease diagnosed after the first line of chemotherapy during second-look surgery can be an indication for intraperitoneal chemotherapy. Another treatment option is intraperitoneal hyperthermic perfusion chemotherapy (IHPC) where the drug is administrated into the peritoneal cavity with the use of extracorporeal closed circuit perfusate circulation at a temperature of 41-42 degrees C. We have started to perform, as a second-line treatment, a combination of one IHPC procedure and four cycles of standard intraperitoneal chemotherapy. In a patient who had previously undergone three different chemotherapy regimens, stabilization of the disease was achieved. In our opinion combining the IHPC procedure with intraperitoneal chemotherapy can be valuable in patients with small volume residual tumor.

Persistent ovarian cancer; Intraperitoneal hyperthermic perfusion chemotherapy; Intraperitoneal chemotherapy; Cytoreductive surgery

[1] Deraco M., Rossi C.R., Pennacchioli E., Guadagni S., Somers D.C., Santoro N. et al.: "Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study". Tumori, 2001, 87, 120.

[2] Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S. et al.: "Intraperitoneal cisplatin and paclitaxel in ovarian cancer". N. Engl. J. Med., 2006, 354, 34.

[3] Spratt J.S., Adcock R.A., Muskovin M., Sherrill W., McKeown J.: "Clinical delivery system for intraperitoneal hyperthermic chemotherapy". Cancer Res., 1980, 40, 256.

[4] Fujimura T., Yonemura Y., Nakagawara H., Kitagawa H., Fushida S., Nishimura G. et al.: "Subtotal perinectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer". Oneal. Rep., 2000, 7, 809.

[5] Fujimoto S., Takahashi M., Mutou T., Kobayashi K., Toyosawa T., Isawa E. et al.: "Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery". Cancer; 1997, 79, 884.

[6] El-Kareh A.W., Secomb T.W.: "A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance". Neoplasia, 2004, 6, 117.

[7] Giovanella B.C., Stehlin J.S. Jr., Morgan A.C.: "Selective lethal effect of supranormal temperature on human neoplastic cells". Cancer Res., 1976, 36, 3944.

[8] Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A. et al.: "lntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for Stage III ovarian cancer". N. Engl. J. Med., 1996, 335, 1950.

[9] Markman M., Bundy B.N., Alberts D.S., Fowler J.M., ClarkPearson D.L., Carson L.F. et al.: "Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume Stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group". J. Clin. Oneal., 2001, 19, 1001.

[10] de Bree E., Romanos J., Michalakis J., Relakis K., Georgoulias V., Melissas J. et al.: "Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin". Anticancer Res., 2003, 23, 3019.

[11] Chatzigeorgiou K., Economou S., Chrysafis G., Dimasis A., Zafiriou G., Setzis K. et al.: "Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP)". Zentralbl. Gynakol., 2003, 125, 424.

[12] Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G. et al.: "Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer". Gynecol. Oncol., 2004, 94, 325.

[13] Hager E.D., Dziambor H., Hohmann D., Muhe N., Strama H.: "Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer". Int. J. Gynecol. Cancer; 2001, 11, 57.

[14] Stephens A.O., Alderman R., Chang D., Edwards G.D., Esquivel J., Sebbag G. et al.: "Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique". Ann. Surg. Oncol., 1999, 6, 790.

[15] Glehen 0., Osinsky D., Cotte E., Kwiatkowski F., Freyer G., Isaac S. et al.: "Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures". Ann. Surg. Oncol., 2003, 10, 863.